Blog detail

Arthritis Pill From Pfizer Wins Support of U.S. Panel
Arthritis Pill From Pfizer Wins Support of U.S. Panel
By Madhu Devireddy In Uncategorized Posted July 18, 2015 0 Comments

New York Times – May 9, 2012

 

A federal advisory panel recommended approval on Wednesday of a rheumatoid arthritis pill that could offer patients an alternative to the injectable medicines already on the market, but several members expressed concern about safety and urged the Food and Drug Administration to require rigorous follow-up studies.

The arthritis advisory committee voted 8 to 2 that the drug, known as tofacitinib, offered enough benefits to overcome potential safety risks, including higher rates of lymphoma and other cancers and serious infections. The agency, which is scheduled to decide on approval by August, usually — but not always — follows the advice of advisory committees.

Pfizer, which is developing tofacitinib, has hailed the drug as one of its most promising prospects as the company works to regain sales after its blockbustercholesterol drug, Lipitor, lost its patent protection last year.

If the drug is approved, it could prove to be a potent competitor to Humira, a drug made by Abbott that brought in nearly $2 billion in sales during the first quarter of this year.

During Pfizer’s presentation to the panel, company officials said the drug’s safety risks were comparable to those of rheumatoid arthritis drugs already on the market. But an F.D.A. reviewer said his analysis showed that cancer rates in the study seemed to increase in higher doses of the drug and over time. It was these safety concerns that led two of the committee members to vote against approval.

“The observation of malignancy rates increasing over time was unexpected and is of major concern,” said the reviewer, Dr. Nikolay P. Nikolov.

Pfizer is asking the agency to approve the drug in both a 5-milligram and 10-milligram dose.

In a statement, Pfizer noted that its trials included about 4,800 patients, one of the largest of its kind. “We believe the clinical trial results … continue

Hours of operation
The Primary Clinic is open: Mon - Fri 8 a.m to 7 p.m and Sat & Sun 8 a.m to 5 p.m
Appointments and Contact Info
To make an appointment call:
209 826-2222
To send a FAX:
209 826-6554
To contact Billing:
209 826-0471
Our Location
KML-LogoFullscreen-LogoGeoRSS-Logo
Dos Palos Apex Health Center

loading map - please wait...

Dos Palos Apex Health Center: 37.012697, -120.744553